Similarly, drug efficacy screening suggested that abatacept, a CTLA-4 fusion protein used for treatment of RA, might be effective for treatment of PBC – but abatacept showed no effect on PBC in the trial by Bowlus et al. (2019).33 Here, CTLA4 is linked to primary biliary cholangitis.